
CLAIMS

1. A solid form of a compound of Formula (I), of a solvate of a compound of Formula (I), or of a cocrystal of a compound of Formula (I):



(I),

wherein the solid form is:

Form 1 of a compound of formula (I), having an X-ray powder diffraction (XRPD) pattern comprising peaks at 16.8, 23.6, and 25.6 degrees 2θ, plus or minus 0.2;

Form 2 of a 1-propanol, acetone, chloroform, or dichloromethane solvate of a compound of formula (I), having an XRPD pattern comprising peaks at 13.6, 14.9, and 21.0 degrees 2θ, plus or minus 0.2;

Form 3 of a MEK, 1-propanol, acetone, dimethyl sulfoxide, *tert*-butylmethyl ether, 2-methyl-1-propanol, or 2-methyl THF solvate of a compound of formula (I), having an XRPD pattern comprising peaks at 17.9, 20.6, and 25.8 degrees 2θ, plus or minus 0.2;

Form 4 of a 2-propanol, 1-propanol, dimethyl sulfoxide, 2-methyl-1-propanol, 1,4-dioxane, chloroform, THF, 2-methoxyethanol, or acetone solvate of a compound of formula (I), having an XRPD pattern comprising peaks at 7.4, 18.0, and 20.7 degrees 2θ, plus or minus 0.2;

Form 5 of an anisole solvate of a compound of formula (I), having an XRPD pattern comprising peaks at 21.0, 22.1, and 25.2 degrees 2θ, plus or minus 0.2;

Form 6 of a hydrate of a compound of formula (I), having an XRPD pattern comprising peaks at 4.8, 19.9, and 26.7 degrees 2θ, plus or minus 0.2;

Form 7 of a MEK, 1-propanol, acetone, or *tert*-butylmethyl ether solvate of a compound of formula (I), having an XRPD pattern comprising peaks at 7.5, 12.3, and 20.7 degrees 2θ, plus or minus 0.2;

Form 8 of a compound of formula (I), having an XRPD pattern comprising peaks at 18.8, 20.8, and 24.5 degrees 2θ, plus or minus 0.2;

Form P1C3 of a cocrystal of a compound of Formula (I) and L-tartaric acid, having an XRPD pattern comprising peaks at 11.2, 17.4, and 17.7 degrees 2θ, plus or minus 0.2;

Form P1C9 of a cocrystal of a compound of Formula (I) and salicylic acid, having an XRPD pattern comprising peaks at 6.9, 10.1, and 12.0 degrees 2θ, plus or minus 0.2; or

Form P2C9 of a cocrystal of a compound of Formula (I) and salicylic acid, having an XRPD pattern comprising peaks at 11.4, 13.4, and 24.0 degrees 2θ, plus or minus 0.2.

2. The solid form of claim 1, wherein the solid form is Form 1 of a compound of formula (I), having an X-ray powder diffraction (XRPD) pattern comprising peaks at 16.8, 23.6, and 25.6 degrees 2θ, plus or minus 0.2.

3. The solid form of claim 2, having an XRPD pattern further comprising at least one peak selected from 14.6 and 21.2 degrees 2θ, plus or minus 0.2.

4. The solid form of claim 2, having an XRPD pattern substantially as shown in FIG. 1.

5. The solid form of claim 2, which exhibits an endothermic event, as characterized by DSC, with an onset temperature at about 255 °C and/or a peak temperature at about 257 °C.

6. The solid form of claim 2, which exhibits a weight loss of about 0.6% upon heating from about 230 °C to about 310 °C.

7. The solid form of claim 2, which exhibits a weight increase of about 0.5 % when subjected to an increase in relative humidity from about 0 to about 90 % relative humidity.

8. The solid form of claim 2, having approximately unit cell dimensions of: a = 11.1 Å, b = 12.8 Å, c = 16.1 Å, α = 90°, β = 90°, and γ = 90°.

9. The solid form of claim 2, which is anhydrous.

10. The solid form of claim 2, which is non-hygroscopic.

11. The solid form of claim 1, wherein the solid form is Form 2 of a 1-propanol, acetone, chloroform, or dichloromethane solvate of a compound of formula (I), having an XRPD pattern comprising peaks at 13.6, 14.9, and 21.0 degrees 2θ, plus or minus 0.2.

12. The solid form of claim 11, having an XRPD pattern further comprising at least one peak selected from 7.4 and 16.7 degrees 2θ, plus or minus 0.2.

13. The solid form of claim 11, having an XRPD pattern substantially as shown in FIG. 4.

14. The solid form of claim 11, having approximately unit cell dimensions of: a = 8.7 Å, b = 13.2 Å, c = 26.0 Å, α = 90°, β = 90°, and γ = 90°.

15. The solid form of claim 1, wherein the solid form is Form 3 of a MEK, 1-propanol, acetone, dimethyl sulfoxide, *tert*-butylmethyl ether, 2-methyl-1-propanol, or 2-methyl THF solvate of a compound of formula (I), having an XRPD pattern comprising peaks at 17.9, 20.6, and 25.8 degrees 2θ, plus or minus 0.2.

16. The solid form of claim 15, having an XRPD pattern further comprising at least one peak selected from 11.7 and 23.5 degrees 2θ, plus or minus 0.2.

17. The solid form of claim 15, having an XRPD pattern substantially as shown in FIG. 9.

18. The solid form of claim 1, wherein the solid form is Form 4 of a 2-propanol, 1-propanol, dimethyl sulfoxide, 2-methyl-1-propanol, 1,4-dioxane, chloroform, THF, 2-methoxyethanol, or acetone solvate of a compound of formula (I), having an XRPD pattern comprising peaks at 7.4, 18.0, and 20.7 degrees 2θ, plus or minus 0.2.

19. The solid form of claim 18, having an XRPD pattern further comprising at least one peak selected from 11.9 and 13.6 degrees 2θ, plus or minus 0.2.

20. The solid form of claim 18, having an XRPD pattern substantially as shown in FIG. 11.

21. The solid form of claim 1, wherein the solid form is Form 5 of an anisole solvate of a compound of formula (I), having an XRPD pattern comprising peaks at 21.0, 22.1, and 25.2 degrees 2θ, plus or minus 0.2.

22. The solid form of claim 21, having an XRPD pattern further comprising at least one peak selected from 14.5 and 19.2 degrees 2θ, plus or minus 0.2.

23. The solid form of claim 21, having an XRPD pattern substantially as shown in FIG. 13.

24. The solid form of claim 1, wherein the solid form is Form 6 of a hydrate of a compound of formula (I), having an XRPD pattern comprising peaks at 4.8, 19.9, and 26.7 degrees 2θ, plus or minus 0.2.

25. The solid form of claim 24, having an XRPD pattern further comprising at least one peak selected from 11.9 and 24.8 degrees 2θ, plus or minus 0.2.

26. The solid form of claim 24, having an XRPD pattern substantially as shown in FIG. 15.

27. The solid form of claim 1, wherein the solid form is Form 7 of a MEK, 1-propanol, acetone, or *tert*-butylmethyl ether solvate of a compound of formula (I), having an XRPD pattern comprising peaks at 7.5, 12.3, and 20.7 degrees 2θ, plus or minus 0.2.

28. The solid form of claim 27, having an XRPD pattern further comprising at least one peak selected from 13.7 and 17.2 degrees 2θ, plus or minus 0.2.

29. The solid form of claim 27, having an XRPD pattern substantially as shown in FIG. 18.

30. The solid form of claim 1, wherein the solid form is Form 8 of a compound of formula (I), having an XRPD pattern comprising peaks at 18.8, 20.8, and 24.5 degrees 2θ, plus or minus 0.2.

31. The solid form of claim 30, having an XRPD pattern further comprising at least one peak selected from 16.0 and 17.9 degrees 2θ, plus or minus 0.2.

32. The solid form of claim 30, having an XRPD pattern substantially as shown in FIG. 20.

33. The solid form of claim 1, wherein the solid form is Form P1C3 of a cocrystal of a compound of Formula (I) and L-tartaric acid, having an XRPD pattern comprising peaks at 11.2, 17.4, and 17.7 degrees 2θ, plus or minus 0.2.

34. The solid form of claim 33, having an XRPD pattern further comprising at least one peak selected from 21.2 and 22.5 degrees 2θ, plus or minus 0.2.

35. The solid form of claim 33, having an XRPD pattern substantially as shown in FIG. 22.

36. The solid form of claim 1, wherein the solid form is Form P1C9 of a cocrystal of a compound of Formula (I) and salicylic acid, having an XRPD pattern comprising peaks at 6.9, 10.1, and 12.0 degrees 2θ, plus or minus 0.2.

37. The solid form of claim 36, having an XRPD pattern further comprising at least one peak selected from 17.8 and 20.0 degrees 2θ, plus or minus 0.2.

38. The solid form of claim 36, having an XRPD pattern substantially as shown in FIG. 24.

39. The solid form of claim 1, wherein the solid form is Form P2C9 of a cocrystal of a compound of Formula (I) and salicylic acid, having an XRPD pattern comprising peaks at 11.4, 13.4, and 24.0 degrees 2θ, plus or minus 0.2.

40. The solid form of claim 39, having an XRPD pattern further comprising at least one peak selected from 25.1 and 26.9 degrees 2θ, plus or minus 0.2.

41. The solid form of claim 39, having an XRPD pattern substantially as shown in FIG. 26.

42. A pharmaceutical composition comprising a solid form of claim 1 and a pharmaceutical acceptable excipient thereof.

43. A pharmaceutical composition consisting essentially of the solid form of claim 1.